Autoantibodies targeting myeloperoxidase, an enzyme in neutrophils; a subtype of ANCA used to diagnose and monitor certain autoimmune vasculitides.
Anti-Myeloperoxidase-Antikörper is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
Anti-Myeloperoxidase-Antikörper becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
Anti-Myeloperoxidase-Antikörper does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
Myeloperoxidase antibodies (MPO-ANCA) are autoantibodies directed against myeloperoxidase, an enzyme found in neutrophil granulocytes. They belong to the antineutrophil cytoplasmic antibody (ANCA) family and typically produce a perinuclear staining pattern (p‑ANCA) on indirect immunofluorescence. MPO‑ANCA are strongly associated with ANCA‑associated vasculitides, particularly microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Testing for MPO‑ANCA aids in the diagnosis, classification, and monitoring of these rare autoimmune conditions that affect small blood vessels.
A result below the laboratory cutoff (commonly <20 U/mL, but lab‑dependent) is considered negative. This indicates no detectable MPO‑ANCA and makes active MPO‑ANCA‑associated vasculitis unlikely. However, very early disease or prior immunosuppressive therapy may yield a negative result despite clinical suspicion.
A result above the reference range (≥20 U/mL in many labs) is considered positive and indicates the presence of anti‑MPO antibodies. This finding supports the diagnosis of an ANCA‑associated vasculitis, especially microscopic polyangiitis or EGPA. Higher titers may correlate with disease activity, but results must be interpreted alongside clinical symptoms and other laboratory findings.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
Anti-Myeloperoxidase-Antikörper becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Myeloperoxidase Antibodies (MPO-ANCA) alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
Most laboratories define a normal (negative) result as below 20 U/mL, but reference ranges are assay‑dependent. Values under the cutoff indicate that MPO‑ANCA are not detected.
A positive MPO‑ANCA test suggests the presence of autoantibodies against myeloperoxidase. It is most commonly seen in microscopic polyangiitis, but also in EGPA and, rarely, in drug‑induced vasculitis or other autoimmune conditions. A positive result should be correlated with clinical findings.
Yes. MPO‑ANCA titers can rise during periods of active vasculitis and fall with effective immunosuppressive treatment. Serial measurements may help monitor disease activity, but treatment decisions should not rely solely on antibody levels.
Anti-Myeloperoxidase-Antikörper does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
For many fatigue-related, inflammatory, hormonal, or recovery-linked markers, interpretation becomes stronger when symptoms, exertion response, and daily function are considered together.
Anti-Myeloperoxidase-Antikörper is rarely meaningful in isolation when fatigue, brain fog, or unstable capacity are central. The fatigue hub provides the broader lab-and-symptom context.
If symptoms worsen after activity with a delay, PEM often explains more than an isolated lab value alone.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
